Cellosaurus logo
expasy logo

Cellosaurus 92-1 [Human bladder carcinoma] (CVCL_W909)

[Text version]
Cell line name 92-1 [Human bladder carcinoma]
Synonyms TCC 92-1
Accession CVCL_W909
Resource Identification Initiative To cite this cell line use: 92-1 [Human bladder carcinoma] (RRID:CVCL_W909)
Comments Part of: UBC-40 urothelial bladder cancer cell line index.
Omics: CNV analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
Sequence variations
  • Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680).
Disease Bladder carcinoma (NCIt: C4912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling 80Y
Category Cancer cell line
Publications

PubMed=9436977; DOI=10.1101/gad.12.2.163
Yeager T.R., DeVries S., Jarrard D.F., Kao C., Nakada S.Y., Moon T.D., Bruskewitz R., Stadler W.M., Meisner L.F., Gilchrist K.W., Newton M.A., Waldman F.M., Reznikoff C.A.
Overcoming cellular senescence in human cancer pathogenesis.
Genes Dev. 12:163-174(1998)

PubMed=10919661
Sarkar S., Julicher K.P., Burger M.S., Della Valle V., Larsen C.-J., Yeager T.R., Grossman T.B., Nickells R.W., Protzel C., Jarrard D.F., Reznikoff C.A.
Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers.
Cancer Res. 60:3862-3871(2000)

PubMed=24367658; DOI=10.1371/journal.pone.0084411
Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H., Knowles M.A.
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
PLoS ONE 8:E84411-E84411(2013)

PubMed=24018021; DOI=10.1016/j.eururo.2013.08.052
Allory Y., Beukers W., Sagrera A., Flandez M., Marques M., Marquez M., van der Keur K.A., Dyrskjot L., Lurkin I., Vermeij M., Carrato A., Lloreta J., Lorente J.A., Carrillo-de-Santa-Pau E., Masius R.G., Kogevinas M., Steyerberg E.W., van Tilborg A.A.G., Abas C., Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.
Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Eur. Urol. 65:360-366(2014)

PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057
Hurst C.D., Platt F.M., Knowles M.A.
Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
Eur. Urol. 65:367-369(2014)

PubMed=25997541; DOI=10.1186/s12864-015-1450-3
Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B., Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G., Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D., Chanock S.J., Valencia A., Real F.X.
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
BMC Genomics 16:403.1-403.16(2015)

PubMed=29732388; DOI=10.3233/BLC-180167
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Bladder Cancer 4:169-183(2018)

Cross-references
Encyclopedic resources Wikidata; Q54605662
Gene expression databases GEO; GSM1567847
GEO; GSM1574585
GEO; GSM1574588
Polymorphism and mutation databases Cosmic; 1046694
Cosmic; 1285106
Cosmic; 2037941
Cosmic; 2050430
Cosmic; 2212690
Entry history
Entry creation17-Jul-2014
Last entry update29-Jun-2023
Version number15